Cyprus Mail
Business International

BioNTech strengthens cancer therapy expertise with US acquisition

biontech 2 vaccine

BioNTech said it was acquiring a production site and a research and development platform from a subsidiary of US biotech company Gilead (GILD.O) to expand its footprint in north America and in novel cancer treatments.

The German biotech firm on Monday said it was buying a solid tumour neoantigen T-cell receptor therapy (TCR-Ts) R&D platform and a manufacturing plant in the city of Gaithersburg in the state of Maryland from Kite Pharma.

T-cell receptors (TCRs) are a class of compounds that make it easier for the body’s immune cells to identify and destroy cancer cells, while TCR-Ts detect targets both inside and outside the cancer cells.

The acquisition will expand BioNTech’s pipeline in individualized cell therapies for cancer patients and add to its existing manufacturing capacities in Idar-Oberstein, Germany, it said.

Kite Pharma will receive a one-time upfront payment, BioNtech said without giving further details.

The deal is expected to close by the end of July, 2021.

Related posts

Renault plans 2,000 job cuts in France as it moves to electric cars

Reuters News Service

UAE economy minister to visit Britain seeking trade deal

Reuters News Service

British Airways owner not planning to tap shareholders for capital

Reuters News Service

Plans in place to protect consumers from soaring gas prices – UK business minister

Reuters News Service

A banking system that facilitates wealth transfer rather than wealth creation

CM Guest Columnist

ECB policies contributing to ultralow interest rates, inflation and inequalities

Les Manison